左旋多巴联合恩他卡朋治疗帕金森病的临床研究

发布时间：2018-03-26 06:53

  本文选题：左旋多巴　切入点：恩他卡朋　出处：《中国临床药理学杂志》2016年14期

【摘要】：目的观察左旋多巴联合恩他卡朋治疗帕金森病的临床疗效及安全性。方法将54例原发性帕金森病患者随机分为对照组27例和试验组27例。对照组予以口服左旋多巴0.25 g,tid;试验组在对照组的基础上,予以口服恩他卡朋0.2 g,tid。2组患者均治疗16周。比较2组患者的临床疗效、血清白细胞介素(IL)-1β、IL-6、丙二醛、超氧化物歧化酶(SOD)和谷胱甘肽过氧化物酶(GSH-Px)水平、统一帕金森病评分量表(UPDRS)评分以及不良反应发生率。结果治疗后,试验组的总有效率为92.59%(25/27例)显著高于对照组的70.37%(19/27例,P0.05)。治疗后,试验组与对照组的血清IL-1β分别为(32.32±0.32),(45.35±6.01)pg·L-1;IL-6分别为(4.03±0.54),(6.78±0.82)pg·L~(-1);丙二醛水平分别为(14.72±2.21),(19.37±2.44)mmol·mg~(-1);UPDRS-Ⅱ评分分别为(3.98±1.56),(11.74±1.25)分;UPDRS-Ⅲ评分分别为(26.43±3.28),(31.54±4.17)分,且试验组治疗后的上述指标均显著低于对照组(P0.05)。治疗后,试验组与对照组的血清SOD分别为(135.55±17.84),(120.93±18.38)U·μg~(-1)、GSH-Px分别为(99.74±12.43),(90.73±10.84)U·μg~(-1),且试验组治疗后的上述指标均显著高于对照组(P0.05)。试验组和对照组的不良反应以神经系统、消化系统和皮肤系统的症状为主,其不良反应发生率分别为11.11%和14.81%,差异无统计学意义(P0.05)。结论左旋多巴联合恩他卡朋治疗帕金森病的临床疗效确切,且不增加不良反应发生率。
[Abstract]:Objective to observe the clinical efficacy and safety of Levodopa combined with Entakaben in the treatment of Parkinson's disease. Methods 54 patients with primary Parkinson's disease were randomly divided into control group (n = 27) and trial group (n = 27). The experimental group was based on the control group. The clinical efficacy, serum levels of IL-6, malondialdehyde (MDA), superoxide dismutase (SOD) and glutathione peroxidase (GSH-Px) were compared between the two groups. Results after treatment, the total effective rate of the trial group was 92.5925 / 27 cases, which was significantly higher than that of the control group (70.37% / 27 cases, P 0.05). The serum IL-1 尾 of test group and control group were 32.32 卤0.32 卤0.32 卤0.32 卤0.32 卤0.32 卤0.32 卤0.32 卤0.32 卤0.32 卤0.32 卤0.32 卤6.01)pg L ~ (-1) and 6.78 卤6.78 卤0.82)pg 路L ~ (-1) of IL-6, respectively, and the level of malondialdehyde (MDA) were 14.72 卤2.21 卤1.37 卤1.37 卤1.56 Mg-1 / 1 respectively. The scores of UPDRS- 鈪，

本文编号：1666837